Pre-treatment pan-immune-inflammation value as a prognostic marker of pazopanib in soft tissue sarcoma.

ABSTRACT:

Background

Increasingly, more evidence has shown that inflammation stress and the tumor microenvironment pose a negative effect on targeted therapy. The neutrophil-to-lymphocyte ratio is considered to be a surrogate biomarker of inflammation and can predict pazopanib treatment effect in non-adipocytic soft-tissue sarcoma (STS). The role of the pan-immune-inflammation value (PIV) in STS is still yet to be determined.

Objectives

We sought whether the pre-treatment PIV could be applied to predict the response of pazopanib in STS.

Design

We conducted a retrospective analysis of 75 patients who had been treated with pazopanib for recurrent or metastatic non-adipocytic STS.

Methods

Our cohort was stratified into either a pre-treatment high PIV group with PIV ⩾310 (

SUBMITTER: Wu CH 

PROVIDER: S-EPMC11523153 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature